Payment Breakdown by Category
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $630.41 | 9 | 80.8% |
| Honoraria | $150.00 | 1 | 19.2% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| GENZYME CORPORATION | $252.57 | 1 | $0 (2017) |
| Celgene Corporation | $161.98 | 1 | $0 (2017) |
| Alexion Pharmaceuticals, Inc. | $150.00 | 1 | $0 (2021) |
| AstraZeneca Pharmaceuticals LP | $104.43 | 2 | $0 (2021) |
| Janssen Biotech, Inc. | $28.91 | 1 | $0 (2019) |
| Novocure Inc. | $25.52 | 1 | $0 (2023) |
| AbbVie Inc. | $21.81 | 1 | $0 (2023) |
| Amgen Inc. | $19.00 | 1 | $0 (2021) |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $16.19 | 1 | $0 (2018) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2023 | $47.33 | 2 | Novocure Inc. ($25.52) |
| 2021 | $186.34 | 3 | Alexion Pharmaceuticals, Inc. ($150.00) |
| 2019 | $28.91 | 1 | Janssen Biotech, Inc. ($28.91) |
| 2018 | $16.19 | 1 | Boehringer Ingelheim Pharmaceuticals, Inc. ($16.19) |
| 2017 | $501.64 | 3 | GENZYME CORPORATION ($252.57) |
All Payment Transactions
10 individual payment records from CMS Open Payments
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 09/12/2023 | AbbVie Inc. | DALVANCE (Drug) | Food and Beverage | In-kind items and services | $21.81 | General |
| Category: ANTI-INFECTIVE | ||||||
| 05/31/2023 | Novocure Inc. | Optune (Device) | Food and Beverage | Cash or cash equivalent | $25.52 | General |
| Category: Oncology | ||||||
| 09/04/2021 | AstraZeneca Pharmaceuticals LP | IMFINZI (Biological) | Food and Beverage | In-kind items and services | $17.34 | General |
| Category: Oncology | ||||||
| 06/30/2021 | Amgen Inc. | Nplate (Biological), XGEVA | Food and Beverage | In-kind items and services | $19.00 | General |
| Category: Hematology | ||||||
| 02/23/2021 | Alexion Pharmaceuticals, Inc. | Soliris (Drug) | Honoraria | Cash or cash equivalent | $150.00 | General |
| Category: Immunology | ||||||
| 05/09/2019 | Janssen Biotech, Inc. | DARZALEX (Biological), IMBRUVICA | Food and Beverage | In-kind items and services | $28.91 | General |
| Category: Oncology | ||||||
| 11/28/2018 | Boehringer Ingelheim Pharmaceuticals, Inc. | GILOTRIF (Drug) | Food and Beverage | In-kind items and services | $16.19 | General |
| Category: ONCOLOGY | ||||||
| 12/13/2017 | Celgene Corporation | — | Food and Beverage | In-kind items and services | $161.98 | General |
| 05/24/2017 | AstraZeneca Pharmaceuticals LP | TAGRISSO (Drug) | Food and Beverage | In-kind items and services | $87.09 | General |
| Category: Oncology | ||||||
| 05/11/2017 | GENZYME CORPORATION | MOZOBIL (Drug) | Food and Beverage | In-kind items and services | $252.57 | General |
| Category: ONCOLOGY | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 6 | 583 | 1,071 | $431,775 | $85,705 |
| 2022 | 7 | 626 | 1,171 | $436,746 | $95,438 |
| 2021 | 9 | 626 | 1,225 | $417,897 | $97,038 |
| 2020 | 8 | 638 | 1,306 | $418,924 | $83,806 |
All Medicare Procedures & Services
39 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2023 | 253 | 556 | $196,824 | $38,221 | 19.4% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2023 | 117 | 206 | $102,382 | $22,490 | 22.0% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 81 | 126 | $44,604 | $7,243 | 16.2% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Facility | 2023 | 39 | 39 | $27,729 | $5,482 | 19.8% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 38 | 50 | $24,850 | $4,421 | 17.8% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 21 | 50 | $12,450 | $3,085 | 24.8% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 21 | 21 | $14,679 | $2,642 | 18.0% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 13 | 23 | $8,257 | $2,122 | 25.7% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2022 | 212 | 477 | $157,314 | $32,278 | 20.5% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2022 | 109 | 220 | $99,440 | $23,298 | 23.4% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 114 | 211 | $69,562 | $14,531 | 20.9% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 50 | 78 | $35,256 | $8,113 | 23.0% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Facility | 2022 | 48 | 48 | $31,008 | $6,710 | 21.6% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 18 | 56 | $12,656 | $2,983 | 23.6% |
| 99223 | Initial hospital inpatient care per day, typically 70 minutes | Facility | 2022 | 16 | 16 | $10,160 | $2,448 | 24.1% |
| 99443 | Telephone medical discussion with physician, 21-30 minutes | Facility | 2022 | 26 | 32 | $4,322 | $2,142 | 49.6% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Facility | 2022 | 22 | 22 | $11,352 | $2,003 | 17.6% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 11 | 11 | $5,676 | $931.25 | 16.4% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Facility | 2021 | 207 | 495 | $159,885 | $34,207 | 21.4% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Facility | 2021 | 119 | 205 | $89,585 | $22,719 | 25.4% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 119 | 251 | $81,073 | $17,183 | 21.2% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Office | 2021 | 40 | 60 | $26,220 | $6,664 | 25.4% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2021 | 21 | 67 | $14,673 | $3,709 | 25.3% |
| 99205 | New patient outpatient visit, total time 60-74 minutes | Facility | 2021 | 23 | 23 | $14,375 | $3,106 | 21.6% |
| 99443 | Physician telephone patient service, 21-30 minutes of medical discussion | Facility | 2021 | 37 | 44 | $5,480 | $2,819 | 51.4% |
About Dr. Todd Clover, MD
Dr. Todd Clover, MD is a Internal Medicine healthcare provider based in Bend, Oregon. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 08/30/2006. The National Provider Identifier (NPI) number assigned to this provider is 1164532107.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Todd Clover, MD has received a total of $780.41 in payments from pharmaceutical and medical device companies, with $47.33 received in 2023. These payments were reported across 10 transactions from 9 companies. The most common payment nature is "Food and Beverage" ($630.41).
As a Medicare-enrolled provider, Clover has provided services to 2,473 Medicare beneficiaries, totaling 4,773 services with total Medicare billing of $361,986. Data is available for 4 years (2020–2023), covering 39 distinct procedure/service records.
Practice Information
- Specialty Internal Medicine
- Other Specialties Hematology & Oncology
- Location Bend, OR
- Active Since 08/30/2006
- Last Updated 04/17/2020
- Taxonomy Code 207R00000X
- Entity Type Individual
- NPI Number 1164532107
Products in Payments
- MOZOBIL (Drug) $252.57
- Soliris (Drug) $150.00
- TAGRISSO (Drug) $87.09
- DARZALEX (Biological) $28.91
- Optune (Device) $25.52
- DALVANCE (Drug) $21.81
- Nplate (Biological) $19.00
- IMFINZI (Biological) $17.34
- GILOTRIF (Drug) $16.19
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Internal Medicine Doctors in Bend
Dr. Mary Carroll, M.d, M.D
Internal Medicine — Payments: $74,687
Bruce Mclellan, M.d, M.D
Internal Medicine — Payments: $19,127
Manish Mehta, Md, MD
Internal Medicine — Payments: $16,763
Erinn Hughes, M.d, M.D
Internal Medicine — Payments: $13,420
Nicholas Buss
Internal Medicine — Payments: $6,759
Michael Widmer, M.d, M.D
Internal Medicine — Payments: $5,824